EMERGENT BIOSOLUTIONS INC. Financial and Nonfinancial Liabilities, Fair Value Disclosure
EMERGENT BIOSOLUTIONS INC. (EBS) had Financial and Nonfinancial Liabilities, Fair Value Disclosure of $12.80 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Fair Value, Net Asset (Liability)
us-gaap:LiabilitiesFairValueDisclosure · last filed 2026-08-06
- 2026-06-30: Financial and Nonfinancial Liabilities, Fair Value Disclosure $12.80M.
- 2026-03-31: Financial and Nonfinancial Liabilities, Fair Value Disclosure $13.30M.
- 2025-12-31: Financial and Nonfinancial Liabilities, Fair Value Disclosure $21.70M.
- 2025-09-30: Financial and Nonfinancial Liabilities, Fair Value Disclosure $14.40M.
| Period end | Financial and Nonfinancial Liabilities, Fair Value Disclosure | Financial and Nonfinancial Liabilities, Fair Value Disclosure as first filed |
|---|---|---|
| 2026-06-30 | $12.80M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $13.30M 10-Q · filed 2026-05-01 | |
| 2025-12-31 | $21.70M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $14.40M 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $9.60M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $6.70M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $16.20M 10-K · filed 2026-02-27 | |
| 2024-09-30 | $13.90M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $4.30M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $5.50M 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $5.60M 10-K · filed 2025-03-04 | |
| 2023-09-30 | $5.40M 10-Q · filed 2023-12-11 | |
| 2023-06-30 | $7.40M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $7.60M 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $8.00M 10-K · filed 2024-03-08 | $6.80M 10-K · filed 2023-03-01 |
| 2022-09-30 | $7.80M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $8.10M 10-Q · filed 2022-08-02 | |
| 2022-03-31 | $7.60M 10-Q · filed 2022-04-29 | |
| 2021-12-31 | $44.50M 10-K/A · filed 2023-12-11 | $43.30M 10-K · filed 2022-02-25 |
| 2021-09-30 | $47.80M 10-Q · filed 2021-11-05 | |
| 2021-06-30 | $49.50M 10-Q · filed 2021-07-30 | |
| 2021-03-31 | $50.60M 10-Q · filed 2021-04-30 | |
| 2020-12-31 | $73.10M 10-K · filed 2022-02-25 | |
| 2013-09-30 | $16.58M 10-Q · filed 2013-11-08 | |
| 2011-12-31 | $4.75M 10-Q · filed 2012-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |